BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for Cell Therapy / CAR-T

Cellectis Secures 82,000 Sq Ft Manufacturing Facility in Raleigh to Compliment Paris Facility

By

CellectisCellectis, a leading French biopharmaceutic company, has signed a lease agreement for an 82,000 sq. ft. manufacturing facility in Raleigh, North Carolina, to complement its existing 14,000 sq. ft. manufacturing facility in Paris, France.

Located at 2500 – 2540 Sumner Boulevard in Raleigh, NC, the new USA facility is owned by Equus Capital Partners and will be used for clinical and commercial production of Cellectis’ leading allogeneic UCART products.

Importantly, the decision will combine the capabilities of Cellectis’ two facilities to advance its manufacturing processes and prepare for potential commercialization of its UCART products in the future. [Read more…]

Australian TGA Approves Novartis’ Kymriah® CAR-T Therapy for Two Blood Cancers

By

Kymriah® (tisagenlecleucel), CAR-T therapy from Novartis, receives TGA approval for treating two aggressive blood cancers

  • Kymriah® is an immunocellular therapy that is a one-time treatment manufactured individually for each patient using the patient’s own T cells, genetically reengineered and programmed to recognise and destroy cancer cells.
  • Kymriah® is approved for the treatment of relapsed or refractory patients with paediatric B-cell acute lymphoblastic leukaemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL)[1]
  • Kymriah® could be a treatment option for about 50 paediatric and young adult ALL patients and 420 adult DLBCL patients who relapse or do not respond to initial therapy[2]
  • Kymriah® is the only chimeric antigen receptor T cell (CAR-T) therapy to receive TGA approval in Australia[1]

[Read more…]

CAR-T Companies: The Meteoric Rise Of Cellular Immunotherapies

By

Learn more about the leading CAR-T therapy companies and the technologies they use to fight cancer.

In this article:

    1. An Introduction to CAR-T Companies
    2. Chimeric Antigen Receptors
    3. Increase in CAR-T Biotech Companies
    4. Burgeoning Market for CAR-T Therapies
    5. A Swell of CAR-T Companies in 2018

Getting to Know the Leaders of the CAR-T Industry

 

An Introduction to CAR-T Companies

Chimeric antigen receptor T-cell therapy (CAR-T) is an approach that is now being explored as an alternative to conventional treatments for several forms of cancer. Thus, CAR-T companies are on the rise, supported by a growing investment flowing into CAR-T research, landmark approvals of CAR-T cell therapies by the U.S. FDA (Kymriah and Yescarta), and major acquisitions within the CAR-T space. Most notably, Celgene snagged Juno Therapeutics for a shocking $9 billion in January 2018, and Gilead acquired Kite Pharma for an astounding $11.9 billion in August 2017.  [Read more…]

BioInformant's World-Class Clients